Compare TOWN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOWN | NAMS |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | Netherlands |
| Employees | 2976 | 100 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | N/A | N/A |
| Metric | TOWN | NAMS |
|---|---|---|
| Price | $35.94 | $28.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $46.75 |
| AVG Volume (30 Days) | 368.8K | ★ 846.0K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.63 | $17.96 |
| Revenue Next Year | $5.18 | $540.65 |
| P/E Ratio | $16.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.91 | $16.79 |
| 52 Week High | $37.86 | $42.00 |
| Indicator | TOWN | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 60.57 | 35.47 |
| Support Level | $34.69 | $23.48 |
| Resistance Level | $37.22 | $37.25 |
| Average True Range (ATR) | 0.83 | 1.83 |
| MACD | 0.01 | -0.64 |
| Stochastic Oscillator | 69.19 | 3.94 |
Towne Bank is a financial services company serving individuals, commercial enterprises and professionals, offering retail and commercial banking services in Virginia and North Carolina. The company has four reportable segments: Banking, which provides loan and deposit services, commercial mortgage brokerage, and investment and asset management services; Mortgage, which originates mortgage loans principally sold in the secondary market through purchase commitments from investors; Resort Vacation Management, which provides residential resort property management services; and Insurance, which provides property, casualty, life and health insurance solutions for businesses, individuals and community organizations through a variety of carriers.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.